Abraxane monotherapy is indicated for the treatment of metastatic breast cancer The recommended dose of Abraxane in combination with gemcitabine is Attachment 1: Product information for AusPAR Abraxane paclitaxel (nab) Abraxis PM Date of Finalisation 17 June This Product. Learn more about ABRAXANE®, including dosing, efficacy, and safety information. This site is intended for US healthcare professionals only.

Author: Mezibar Moogutilar
Country: Monaco
Language: English (Spanish)
Genre: Life
Published (Last): 16 October 2014
Pages: 328
PDF File Size: 18.88 Mb
ePub File Size: 1.41 Mb
ISBN: 263-8-21818-669-7
Downloads: 80147
Price: Free* [*Free Regsitration Required]
Uploader: Kagalabar

Eligible patients include those with acute infusion reactions with paclitaxel or docetaxel considered by treating physicians to be a abraxae of the vehicle for the taxanes Cremophor and polysorbate 80severe toxicity from previous administration of other taxanes, or severe toxicity that might be attributable to premedications for example, steroids used for the administration of the taxane. J Natl Cancer Inst.

Nab-paclitaxel was well tolerated, with mild sensory neuropathy grade 1 or 2 occurring in approximately Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Women with mbc treated with single-agent nab-paclitaxel between June and December were included in this analysis.

In our small single-institution retrospective study, most women with mbc who received nab-paclitaxel experienced some degree of clinical benefit qw The second interim analysis demonstrated that nab-paclitaxel was highly unlikely to be superior to paclitaxel for pu survival 9. The small study population and retrospective nature of the analysis represent significant limitations in interpreting its results.

Demographic and treatment characteristics of patients with metastatic breast cancer receiving nab-paclitaxel. SD has received research support from Celgene Canada, but no compensation abrxxane received for the preparation of the present manuscript. National Center for Biotechnology InformationU. Copyright Multimed Inc. The odds ratio for achieving clinical benefit with the qw schedule was 2.


The remaining authors have no financial conflicts of abraxwne to disclose. Most women receiving nab-paclitaxel qw Survival abraxxane for patients who achieved and did not achieve clinical benefit from nab-paclitaxel. In this group, mean age was 57 years range: Cancer and Leukemia Group B trial In addition, there was a potential imbalance in prognostic factors among patients who received the qw schedule and those who received the q3w schedule of nab-paclitaxel.

Clinical outcomes data in patients with metastatic breast abrwxane receiving nab-paclitaxel on a weekly qw and everyweeks q3w schedule. Sensory neuropathy was the primary toxicity Table i summarizes patient demographics and treatment characteristics. J Clin Oncol ; Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.

Cremophor EL—mediated alteration of paclitaxel distribution in human blood: Grade 2 fatigue was reported in 4 patients 9. Find articles by S. A partial response to nab-paclitaxel therapy abrxane seen in 4 patients 9. TABLE II Clinical outcomes data in patients with metastatic breast cancer receiving nab-paclitaxel on a weekly qw and everyweeks q3w schedule.

ABRAXANE – Prescribing Information

Peripheral neuropathy induced by paclitaxel: Data were collected retrospectively on a select group of patients who received nab-paclitaxel if they had private insurance coverage or met the eligibility criteria for the Ontario New Drug Funding Program, creating a potential for selection bias. Patients who received coverage for nab-paclitaxel through the Ontario New Drug Funding Program or third-party funding private insurance were included.

In the Cox proportional hazards analysis, achievement of clinical benefit hr: Nab-paclitaxel treatment was given to 20 patients Clinical Benefit Radiologic and clinical assessments were performed at the discretion of the treating physician. Clinical benefit was defined as partial or complete response or stable disease by clinical or radiologic evaluation, or both at 6 months or more.


ABRAXANE | Full Prescribing Information

Find articles by N. Find articles by J. Paclitaxel is entrapped by the formation of plasma Cremophor EL micelles, which can cause reduced drug clearance, nonlinear pharmacokinetics, and free drug fraction These synthetic solvents are associated with the development of acute hypersensitivity reactions and peripheral neuropathy 4 and so require premedication with corticosteroids, antihistamines, and H 2 a ntagonists Taxotere P I: Articles from Current Oncology are provided here courtesy of Multimed Inc.

Molecular basis for the development of novel taxanes in the treatment of metastatic breast cancer. For women with metastatic breast cancer mbctaxanes 1 are an established treatment option, both as monotherapy and in combination 23.

Importantly, nab-paclitaxel has demonstrated limited taxane cross-resistance.

Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Clinical benefit was based on clinical and radiologic assessments for example, computed tomography imaging of patients, which were requested by the treating physicians at variable points in time. Albumin-bound paclitaxel ab-pac versus docetaxel for first-line treatment of metastatic breast cancer mbc: Traditional solvent-based taxanes have been shown to be beneficial in the treatment of mbc.

That feature is of particular clinical importance for women with early-stage breast cancer who relapse within 12 months of exposure to a solvent-based taxane.